A Prospective Study of Tuberculosis and Human Immunodeficiency Virus Infection: Clinical Manifestations and Factors Associated with Survival
Open Access
- 1 April 1997
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 24 (4) , 661-668
Abstract
We prospectively studied the effect of human immunodeficiency virus (HIV) infection on the presentation and outcome of tuberculosis. A total of 216 patients with tuberculosis were identified; 162 (75%) of these patients were tested for antibodies to HIV; 92 (57%) were seropositive. The patients who were seropositive for HIV were more likely to be male and Hispanic and to have been homeless or incarcerated. Eighty-one percent of these patients had CD4 lymphocyte counts of ⩽200/mm3. The seropositive patients had extrapulmonary tuberculosis more often than did the seronegative patients (odds ratio [OR], 2.3; 95% confidence interval [CI], 1.2–4.8). Smears for acid-fast bacilli were positive more often for non-HIV-infected patients with pulmonary tuberculosis (74.5%) than for HIV-infected patients (54.3%) [OR, 2.46; 95% CI, 1.01–6.02]—even those with focal or cavitary disease. A delay in initiating therapy was associated with in-hospital mortality: the median time from admission to the start of treatment was 4 days for patients who survived and 15 days for those who died (P = .02). The median survival was 22.7 months for HIV-infected patients who did not die during the initial hospitalization. Factors independently associated with reduced rates of survival included the severity of immunodeficiency, nonuse of directly observed therapy, infection due to drug-resistant Mycobacterium tuberculosis, and a history of injection drug use.Keywords
This publication has 32 references indexed in Scilit:
- Race, Sex, Drug Use, and Progression of Human Immunodeficiency Virus DiseaseNew England Journal of Medicine, 1995
- Pulmonary Tuberculosis in HIV-Infected Patients in Zaire — A Controlled Trial of Treatment for Either 6 or 12 MonthsNew England Journal of Medicine, 1995
- Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'IvoireThe Lancet, 1995
- The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in ZambiaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1995
- Transmission of Tuberculosis in New York City -- An Analysis by DNA Fingerprinting and Conventional Epidemiologic MethodsNew England Journal of Medicine, 1994
- Association of Tuberculosis Infection With Increased Time in or Admission to the New York City Jail SystemJAMA, 1993
- The Emergence of Drug-Resistant Tuberculosis in New York CityNew England Journal of Medicine, 1993
- High Risk of Active Tuberculosis in HIV-Infected Drug Users With Cutaneous AnergyJAMA, 1992
- Treatment of Tuberculosis in Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1991
- A Prospective Study of the Risk of Tuberculosis among Intravenous Drug Users with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1989